GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelira Therapeutics Ltd (ASX:ZLD) » Definitions » Debt-to-Asset

Zelira Therapeutics (ASX:ZLD) Debt-to-Asset : 0.53 (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Zelira Therapeutics Debt-to-Asset?

Zelira Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$1.51 Mil. Zelira Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.21 Mil. Zelira Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was A$3.23 Mil. Zelira Therapeutics's debt to asset for the quarter that ended in Dec. 2023 was 0.53.


Zelira Therapeutics Debt-to-Asset Historical Data

The historical data trend for Zelira Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zelira Therapeutics Debt-to-Asset Chart

Zelira Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.02 0.01 0.01 0.01

Zelira Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.53

Competitive Comparison of Zelira Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Zelira Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zelira Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Zelira Therapeutics's Debt-to-Asset falls into.



Zelira Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Zelira Therapeutics's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Zelira Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zelira Therapeutics  (ASX:ZLD) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Zelira Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Zelira Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Zelira Therapeutics (ASX:ZLD) Business Description

Traded in Other Exchanges
Address
101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.

Zelira Therapeutics (ASX:ZLD) Headlines

No Headlines